82 related articles for article (PubMed ID: 32392725)
41. Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas.
Rieber J; Schmitt J; Warth A; Muley T; Kappes J; Eichhorn F; Hoffmann H; Heussel CP; Welzel T; Debus J; Thomas M; Steins M; Rieken S
Eur J Med Res; 2015 Aug; 20(1):64. PubMed ID: 26272455
[TBL] [Abstract][Full Text] [Related]
42. Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy.
Fasano M; Della Corte CM; Papaccio F; Ciardiello F; Morgillo F
J Thorac Oncol; 2015 Aug; 10(8):1133-41. PubMed ID: 26039012
[TBL] [Abstract][Full Text] [Related]
43. Predictors of survival after operation among patients with large cell neuroendocrine carcinoma of the lung.
Eichhorn F; Dienemann H; Muley T; Warth A; Hoffmann H
Ann Thorac Surg; 2015 Mar; 99(3):983-9. PubMed ID: 25596870
[TBL] [Abstract][Full Text] [Related]
44. Diagnosis and treatment of neuroendocrine lung tumors.
Sánchez de Cos Escuín J
Arch Bronconeumol; 2014 Sep; 50(9):392-6. PubMed ID: 24685201
[TBL] [Abstract][Full Text] [Related]
45. Clinicopathological features and the impact of the new TNM classification of malignant tumors in patients with pulmonary large cell neuroendocrine carcinoma.
Iyoda A; Jiang SX; Travis WD; Kurouzu N; Ogawa F; Amano H; Sato Y; Rusch VW; Saegusa M; Satoh Y
Mol Clin Oncol; 2013 May; 1(3):437-443. PubMed ID: 24649189
[TBL] [Abstract][Full Text] [Related]
46. A genomics-based classification of human lung tumors.
;
Sci Transl Med; 2013 Oct; 5(209):209ra153. PubMed ID: 24174329
[TBL] [Abstract][Full Text] [Related]
47. The differences of biological behavior based on the clinicopathological data between resectable large-cell neuroendocrine carcinoma and small-cell lung carcinoma.
Kinoshita T; Yoshida J; Ishii G; Aokage K; Hishida T; Nagai K
Clin Lung Cancer; 2013 Sep; 14(5):535-40. PubMed ID: 23792008
[TBL] [Abstract][Full Text] [Related]
48. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study.
Le Treut J; Sault MC; Lena H; Souquet PJ; Vergnenegre A; Le Caer H; Berard H; Boffa S; Monnet I; Damotte D; Chouaid C
Ann Oncol; 2013 Jun; 24(6):1548-52. PubMed ID: 23406729
[TBL] [Abstract][Full Text] [Related]
49. Comparison of chemotherapeutic efficacy between LCNEC diagnosed using large specimens and possible LCNEC diagnosed using small biopsy specimens.
Tokito T; Kenmotsu H; Watanabe R; Ito I; Shukuya T; Ono A; Nakamura Y; Tsuya A; Naito T; Murakami H; Takahashi T; Ohde Y; Kondo H; Endo M; Kameya T; Nakajima T; Mori K; Yamamoto N
Int J Clin Oncol; 2014 Feb; 19(1):63-7. PubMed ID: 23250620
[TBL] [Abstract][Full Text] [Related]
50. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?
Sun JM; Ahn MJ; Ahn JS; Um SW; Kim H; Kim HK; Choi YS; Han J; Kim J; Kwon OJ; Shim YM; Park K
Lung Cancer; 2012 Aug; 77(2):365-70. PubMed ID: 22579297
[TBL] [Abstract][Full Text] [Related]
51. Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens.
Shimada Y; Niho S; Ishii G; Hishida T; Yoshida J; Nishimura M; Yoh K; Goto K; Ohmatsu H; Ohe Y; Nagai K
Lung Cancer; 2012 Mar; 75(3):368-73. PubMed ID: 21920624
[TBL] [Abstract][Full Text] [Related]
52. Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience.
Sarkaria IS; Iyoda A; Roh MS; Sica G; Kuk D; Sima CS; Pietanza MC; Park BJ; Travis WD; Rusch VW
Ann Thorac Surg; 2011 Oct; 92(4):1180-6; discussion 1186-7. PubMed ID: 21867986
[TBL] [Abstract][Full Text] [Related]
53. Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer.
Igawa S; Watanabe R; Ito I; Murakami H; Takahashi T; Nakamura Y; Tsuya A; Kaira K; Naito T; Endo M; Yamamoto N; Kameya T
Lung Cancer; 2010 Jun; 68(3):438-45. PubMed ID: 19699548
[TBL] [Abstract][Full Text] [Related]
54. Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma.
Iyoda A; Hiroshima K; Moriya Y; Iwadate Y; Takiguchi Y; Uno T; Nakatani Y; Yoshino I
J Thorac Cardiovasc Surg; 2009 Aug; 138(2):446-53. PubMed ID: 19619794
[TBL] [Abstract][Full Text] [Related]
55. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.
Bilimoria KY; Stewart AK; Winchester DP; Ko CY
Ann Surg Oncol; 2008 Mar; 15(3):683-90. PubMed ID: 18183467
[No Abstract] [Full Text] [Related]
56. Pulmonary large cell neuroendocrine carcinoma: its place in the spectrum of pulmonary carcinoma.
Iyoda A; Hiroshima K; Nakatani Y; Fujisawa T
Ann Thorac Surg; 2007 Aug; 84(2):702-7. PubMed ID: 17643676
[TBL] [Abstract][Full Text] [Related]
57. Large-cell neuroendocrine carcinoma of the lung.
Fernandez FG; Battafarano RJ
Cancer Control; 2006 Oct; 13(4):270-5. PubMed ID: 17075564
[TBL] [Abstract][Full Text] [Related]
58. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma.
Iyoda A; Hiroshima K; Moriya Y; Takiguchi Y; Sekine Y; Shibuya K; Iizasa T; Kimura H; Nakatani Y; Fujisawa T
Ann Thorac Surg; 2006 Nov; 82(5):1802-7. PubMed ID: 17062251
[TBL] [Abstract][Full Text] [Related]
59. Prognostic impact of large cell neuroendocrine histology in patients with pathologic stage Ia pulmonary non-small cell carcinoma.
Iyoda A; Hiroshima K; Moriya Y; Sekine Y; Shibuya K; Iizasa T; Nakatani Y; Fujisawa T
J Thorac Cardiovasc Surg; 2006 Aug; 132(2):312-5. PubMed ID: 16872955
[TBL] [Abstract][Full Text] [Related]
60. Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases.
Veronesi G; Morandi U; Alloisio M; Terzi A; Cardillo G; Filosso P; Rea F; Facciolo F; Pelosi G; Gandini S; Calabrò F; Casali C; Marulli G; Spaggiari L
Lung Cancer; 2006 Jul; 53(1):111-5. PubMed ID: 16697073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
